Loading...
XSHE
300009
Market cap2.09bUSD
Oct 09, Last price  
8.53CNY
1D
1.79%
1Q
3.65%
Jan 2017
13.59%
IPO
165.07%
Name

Anhui Anke Biotechnology Group Co Ltd

Chart & performance

D1W1MN
XSHE:300009 chart
P/E
19.38
P/S
5.38
EPS
0.44
Div yield, %
2.98%
Shrs. gr., 5y
0.39%
Rev. gr., 5y
9.24%
Revenues
2.65b
+4.36%
127,769,584125,874,083156,490,022190,643,971227,930,127267,916,554337,940,099430,346,121542,405,932635,755,074849,216,4331,096,268,3141,461,550,2021,712,529,6681,701,417,2152,168,765,2052,331,062,7262,865,752,0592,536,042,7802,646,519,767
Net income
735m
+4.00%
15,727,07822,713,57234,552,89444,570,47151,983,69163,322,66073,945,18889,870,073109,851,480136,254,705197,302,812277,742,631263,171,609124,465,873358,955,402206,629,503703,260,296847,229,435706,948,371735,192,705
CFO
863m
+25.95%
29,662,11435,098,07926,043,95438,674,86547,427,2117,180,61153,800,82553,213,032108,684,214118,734,165258,005,072280,625,013287,490,590295,627,531464,796,376592,171,625698,977,608952,970,899685,371,947863,220,471
Dividend
May 29, 20260.25 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anhui Anke Biotechnology (Group) Co., Ltd. is engaged in the research, manufacturing, and global distribution of pharmaceutical goods, serving both domestic Chinese and international markets. Its flagship offerings include Ansomone, a brand of recombinant human growth hormone administered via injection, and the Anterferon line, which comprises recombinant human interferon alpha 2b in various forms such as lyophilized powder, liquid, and prefilled syringes for injection, alongside creams, eye drops, and suppositories. The company also supplies an array of diagnostic kits, including those for detecting anti-sperm antibodies, performing semen leukocyte peroxidase staining, single-use semen processing, sperm hypo-osmotic staining, assessing sperm viability, analyzing sperm morphology, determining sperm acrosin levels, identifying sperm DNA fragmentation, and for leptin and immunohistochemical analyses. Furthermore, their product portfolio extends to adhesive bandages, liquid oral medications, various topical formulations (including creams and ointments), active pharmaceutical ingredients (APIs) derived from peptides, cosmetic and anti-aging treatments, and synthetic pharmaceutical compounds available as powders, dripping pills, and both tablets and capsules. Moreover, Anke Biotechnology offers genetic testing solutions, encompassing kits for autosomal, sex chromosome, and combined autosomal and sex chromosome analyses, along with complete paternity testing packages. They also develop biological immunotherapy treatments for tumors and provide specialized DNA testing services. Established in 2000, the firm's headquarters are situated in Hefei, China.

Key people

Chenghao Hu
Chief Financial Officer · since 2023
Hai Sheng
Senior Vice President · since 2019
Jianping Yao
Senior Vice President · since 2025
Hui Zhao
Rotating Executive President, Senior Vice President, Director · since 2025
Xueke Bao
Vice President · since 2023
Liansheng Cheng
Vice President · since 2025
Ta Wei Chou
Vice President · since 2023
Yinghui Dou
Vice President · since 2022
Chunyan Lu
Vice President · since 2023
Hongyi Yao
Vice President · since 2023
Junpei Jiang
Chief Purchasing Officer, Director · since 2022
Kun Li
Secretary of the Board, Director · since 2022
Xianyu Du
Chief Technology Officer, Staff Elected Director · since 2025
Lihua Song
Chairman of the Board, President · since 1993
Liming Song
Vice Chairman of the Board · since 2003
Yongbin Wang
Director · since 2023
Yuanyuan Zhou
Vice Chairman of the Board · since 2024
Feihu Chen
Independent Director · since 2022
Xiaoping Geng
Independent Director · since 2022
Lu Wang
Independent Director · since 2025
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT